10 Einträge gefunden

1. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

   1. Jonas, Brian A
   2. Wei, Andrew H
   3. Recher, Christian
   4. DiNardo, Courtney D
   5. Jang, Jun-Ho
   6. Pratz, Keith
   7. Panayiotidis, Panayiotis

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

   1. Fiedler, Walter
   2. Montesinos, Pau
   3. Schliemann, Christoph
   4. Middeke, Jan
   5. Vasu, Sumithira
   6. Scholz, Christian W
   7. Esteve, Jordi

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

   1. Wei, Andrew H
   2. Panayiotidis, Panayiotis
   3. Montesinos, Pau
   4. Laribi, Kamel
   5. Ivanov, Vladimir
   6. Kim, Inho
   7. Novak, Jan

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

   1. Heuser, Michael
   2. Smith, B Douglas
   3. Fiedler, Walter
   4. Sekeres, Mikkael A
   5. Montesinos, Pau
   6. Leber, Brian
   7. Merchant, Akil

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Author Correction:6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

   1. Wei, Andrew H
   2. Panayiotidis, Panayiotis
   3. Montesinos, Pau
   4. Laribi, Kamel
   5. Ivanov, Vladimir
   6. Kim, Inho
   7. Novak, Jan

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)

   1. Wei, Andrew H
   2. Panayiotidis, Panayiotis
   3. Montesinos, Pau
   4. Laribi, Kamel
   5. Ivanov, Vladimir
   6. Kim, Inho
   7. Novak, Jan

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

   1. Heuser, Michael
   2. Smith, B Douglas
   3. Fiedler, Walter
   4. Sekeres, Mikkael A
   5. Montesinos, Pau
   6. Leber, Brian
   7. Merchant, Akil

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
8. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

   1. Cortes, Jorge E
   2. Heidel, Florian H
   3. Fiedler, Walter
   4. Smith, B Douglas
   5. Robak, Tadeusz
   6. Montesinos, Pau
   7. Candoni, Anna

   2020 - Forschungsinformationssystem des UKE
9. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial

   1. Wei, Andrew Henry
   2. Montesinos, Pau
   3. Ivanov, Vladimir
   4. DiNardo, Courtney D
   5. Novak, Jan
   6. Laribi, Kamel
   7. Kim, Inho

   2020 - Forschungsinformationssystem des UKE
10. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    1. Cortes, Jorge E
    2. Heidel, Florian H
    3. Hellmann, Andrzej
    4. Fiedler, Walter
    5. Smith, B Douglas
    6. Robak, Tadeusz
    7. Montesinos, Pau

    2019 - Forschungsinformationssystem des UKE